Best practice & research. Clinical endocrinology & metabolism最新文献_第9页

Coronavirus disease 2019 and vitamin D 2019冠状病毒病和维生素D

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-07-01 DOI: 10.1016/j.beem.2023.101791

Nitin Kapoor MD(Medicine), DM(Endocrine), PhD(University of Melbourne) (Professor of Endocrinology) , Sanjay Kalra MD(Medicine), DM(Endocrine) (Consultant Endocrinologist)

引用次数: 0

COVID-19 vaccination and thyroiditis 新冠肺炎疫苗接种和甲状腺炎。

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-07-01 DOI: 10.1016/j.beem.2023.101759

Süleyman Nahit Şendur (Associate Professor) , Seda Hanife Oğuz (Associate Professor) , Uğur Ünlütürk (Professor)

引用次数: 2

Management of patients with statin intolerance 他汀类药物不耐受患者的管理

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-05-01 DOI: 10.1016/j.beem.2022.101714

Alexandra Nicole Martirossian MD (Endocrinology Fellow), Anne Carol Goldberg MD (Professor of Medicine)

引用次数: 5

Recent advances in lipidology 脂质学的最新进展

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-05-01 DOI: 10.1016/j.beem.2023.101750

Kenneth R. Feingold (Professor Emeritus), Alan Chait (Professor Emeritus)

引用次数: 0

Angiopoietin-like 3: An important protein in regulating lipoprotein levels 血管生成素样3:调节脂蛋白水平的重要蛋白

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-05-01 DOI: 10.1016/j.beem.2022.101688

Kendall H. Burks (BS, MD-PhD Candidate) , Debapriya Basu (PhD, Research Assistant Professor) , Ira J. Goldberg (MD, Professor of Medicine) , Nathan O. Stitziel (MD, PhD, Associate Professor of Medicine)

{"title":"Angiopoietin-like 3: An important protein in regulating lipoprotein levels","authors":"Kendall H. Burks (BS, MD-PhD Candidate) , Debapriya Basu (PhD, Research Assistant Professor) , Ira J. Goldberg (MD, Professor of Medicine) , Nathan O. Stitziel (MD, PhD, Associate Professor of Medicine)","doi":"10.1016/j.beem.2022.101688","DOIUrl":"10.1016/j.beem.2022.101688","url":null,"abstract":"<div>ANGPTL3 has emerged as a therapeutic target whose inhibition results in profound reductions of plasma lipids, including atherogenic triglyceride-rich lipoproteins and low-density lipoprotein cholesterol. The identification of ANGPTL3 deficiency as a cause of familial combined hypolipidemia in humans hastened the development of anti-ANGPTL3 therapeutic agents, including evinacumab (a monoclonal antibody inhibiting circulating ANGPTL3), vupanorsen (an antisense oligonucleotide [ASO] targeting hepatic ANGPTL3 mRNA for degradation), and others. Advances have also been made in ANGPTL3 vaccination and gene editing strategies, with the former still in preclinical phases and the latter in preparation for Phase 1 trials. Here, we review the discovery of ANGPTL3 as an important regulator of lipoprotein metabolism, molecular characteristics of the protein, mechanisms by which it regulates plasma lipids, and the clinical development of anti-ANGPTL3 agents. The clinical success of therapies inhibiting ANGPTL3 highlights the importance of this target as a novel approach in treating refractory hypertriglyceridemia and hypercholesterolemia.</div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 3","pages":"Article 101688"},"PeriodicalIF":7.4,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10220246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Supporting evidence for lipoprotein(a) measurements in clinical practice 临床实践中脂蛋白(a)测量的支持证据

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-05-01 DOI: 10.1016/j.beem.2023.101746

Anastasiya Matveyenko MA, MS (Staff Associate), Marianna Pavlyha MD (Doctoral Scientist), Gissette Reyes-Soffer MD (Assistant Professor of Medicine)

{"title":"Supporting evidence for lipoprotein(a) measurements in clinical practice","authors":"Anastasiya Matveyenko MA, MS (Staff Associate), Marianna Pavlyha MD (Doctoral Scientist), Gissette Reyes-Soffer MD (Assistant Professor of Medicine)","doi":"10.1016/j.beem.2023.101746","DOIUrl":"10.1016/j.beem.2023.101746","url":null,"abstract":"<div>High levels of lipoprotein(a) [Lp(a)] are causal for development of atherosclerotic cardiovascular disease and highly regulated by genetics. Levels are higher in Blacks compared to Whites, and in women compared to men. Lp(a)’s main protein components are apolipoprotein (apo) (a) and apoB100, the latter being the main component of Low-Density Lipoprotein (LDL) particles. Studies have identified Lp(a) to be associated with inflammatory, coagulation and wound healing pathways. Lack of validated and accepted assays to measure Lp(a), risk cutoff values, guidelines for diagnosis, and targeted therapies have added challenges to the field. Scientific efforts are ongoing to address these, including studies evaluating the cardiovascular benefits of decreasing Lp(a) levels with targeted apo(a) lowering treatments. This review will provide a synopsis of evidence-based effects of high Lp(a) on disease presentation, highlight available guidelines and discuss promising therapies in development. We will conclude with current clinical information and future research needs in the field.</div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 3","pages":"Article 101746"},"PeriodicalIF":7.4,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9705962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of endocrine disorders on lipids and lipoproteins 内分泌失调对血脂和脂蛋白的影响

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-05-01 DOI: 10.1016/j.beem.2022.101667

Connie B. Newman MD (Adjunct Professor of Medicine)

{"title":"Effects of endocrine disorders on lipids and lipoproteins","authors":"Connie B. Newman MD (Adjunct Professor of Medicine)","doi":"10.1016/j.beem.2022.101667","DOIUrl":"10.1016/j.beem.2022.101667","url":null,"abstract":"<div>Endocrine diseases may be associated with dyslipidaemia and may increase atherosclerotic cardiovascular disease (ASCVD) risk. This chapter describes changes in lipids and lipoproteins in diseases of the pituitary, thyroid, adrenal glands, ovaries, and testes, the mechanisms for these changes, ASCVD risk in these endocrine disorders, and whether treatment of the endocrine disorder improves the lipid profile and reduces ASCVD risk. Acromegaly, GH deficiency, Cushing syndrome, chronic glucocorticoid replacement, hypothyroidism, PCOS and male hypogonadism can increase LDL-C and/or TG. Marked reductions in LDL-C are associated with hyperthyroidism, and extremely low HDL-C levels with testosterone and/or other anabolic steroid abuse. Acromegaly, GH deficiency, Cushing syndrome, and chronic glucocorticoid replacement are associated with increased ASCVD risk. Treatment of acromegaly, GH deficiency, hypothyroidism, Cushing syndrome, and testosterone deficiency reduce LDL-C, although statin therapy may still be needed. Effects on ASCVD are not known.</div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 3","pages":"Article 101667"},"PeriodicalIF":7.4,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9343049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Approach to patients with elevated low-density lipoprotein cholesterol levels 低密度脂蛋白胆固醇水平升高患者的治疗方法

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-05-01 DOI: 10.1016/j.beem.2022.101658

Kenneth R. Feingold MD (Emeritus Professor of Medicine) , Alan Chait MD (Professor Emeritus, Department of Medicine)

{"title":"Approach to patients with elevated low-density lipoprotein cholesterol levels","authors":"Kenneth R. Feingold MD (Emeritus Professor of Medicine) , Alan Chait MD (Professor Emeritus, Department of Medicine)","doi":"10.1016/j.beem.2022.101658","DOIUrl":"10.1016/j.beem.2022.101658","url":null,"abstract":"<div>Elevated low-density lipoprotein cholesterol (LDL-C) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and lowering LDL-C levels reduces the risk of ASCVD. In patients with elevated LDL-C levels it is important to consider whether lifestyle, other medical conditions, medications, or genetic factors could be causing or contributing to the elevation. There are guidelines from various organizations outlining the approach to lowering LDL-C levels but while these guidelines agree on many issues there are numerous areas where recommendations are discordant. In this review, we outline several principles that will help in deciding who and how to treat patients with elevated LDL-C levels. Specifically, we discuss evidence indicating that the sooner one initiates therapy the better and the greater the reduction in LDL-C the better. Additionally, the higher the LDL-C level and the higher the risk of ASCVD, the greater the benefits of treatment. Using these principles will help in making decisions regarding the treatment of LDL-C levels.</div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 3","pages":"Article 101658"},"PeriodicalIF":7.4,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9348746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I 高密度脂蛋白和载脂蛋白A-I的多效性

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-05-01 DOI: 10.1016/j.beem.2022.101689

Shane R. Thomas Head of Pathology, Yunjia Zhang Postdoctoral Scientist, Kerry-Anne Rye Deputy Head, School of Medical Sciences

{"title":"The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I","authors":"Shane R. Thomas Head of Pathology, Yunjia Zhang Postdoctoral Scientist, Kerry-Anne Rye Deputy Head, School of Medical Sciences","doi":"10.1016/j.beem.2022.101689","DOIUrl":"10.1016/j.beem.2022.101689","url":null,"abstract":"<div>The high density lipoprotein (HDL) fraction of human plasma consists of multiple subpopulations of spherical particles that are structurally uniform, but heterogeneous in terms of size, composition and function. Numerous epidemiological studies have established that an elevated high density lipoprotein cholesterol (HDL-C) level is associated with decreased cardiovascular risk. However, with several recent randomised clinical trials of HDL-C raising agents failing to reduce cardiovascular events, contemporary research is transitioning towards clinical development of the cardioprotective functions of HDLs and the identification of functions that can be exploited for treatment of other diseases. This review describes the origins of HDLs and the causes of their compositional and functional heterogeneity. It then summarises current knowledge of how cardioprotective and other functions of HDLs are regulated. The final section of the review summarises recent advances in the clinical development of HDL-targeted therapies.</div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 3","pages":"Article 101689"},"PeriodicalIF":7.4,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9406921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Approach to patients with hypertriglyceridemia 高甘油三酯血症的治疗方法

IF 7.4 1区医学

Best practice & research. Clinical endocrinology & metabolism Pub Date : 2023-05-01 DOI: 10.1016/j.beem.2022.101659

Alan Chait (Professor Emeritus) , Kenneth R. Feingold (Emeritus Professor of Medicine)

引用次数: 2